Novosti
Khirurgii
This journal is
indexed in Scopus









Year 2010 Vol. 18 No 4

GENERAL AND SPECIAL SURGERY

L.V. KOVALCHUK, V.V. POTEMKIN, T.N. BALDINA, P.B. BARBIN

IMMUNOTHERAPY AT TYPE 2 DIABETIS COMPLICATED BY DIABETIC FOOT SYNDROME, BY THE COMPLEX OF NATURAL CYTOKINES AND ANTIMICROBIAL PEPTIDES

Objectives. Evaluation of the clinical efficacy of the preparation «Syperlymph» in the complex treatment of the patients with diabetic foot syndrome (DFS).
Methods. The results of examination and treatment of 75 patients with DFS are analyzed in the research. The patients were divided into two groups according to the character of the disease and therapy schemes. The first group included 25 (33,3%) patients to whom conventional treatment was applied (antibacterial therapy, disaggregants, angioprotectors, antioxidants, correction of the hyperglycemia level, surgical treatment, dressing with the ointment «Levomekol»). 50 (66,7%) patients with pyo-necrotic lesions of the foot made up the second group; in these patients, together with conventional treatment, immunotherapy with the preparation «Syperlymph» was used. Control group consisting of 25 persons was presented by healthy people.
Results. It is established that immunotherapy application of the complex of natural cytokines and antimicrobial peptides at type 2 diabetes mellitus complicated by diabetic foot syndrome is pathogenetically justified. There is reduction of the activity of the lipid peroxidation as well as stabilization of antioxidant protection of the blood, decrease in endogenous intoxication, normalization of the phagocyte immunity, level of circulating immunoglobulins of the blood.
Conclusions. Immunotherapy with the preparation «Syperlymph» is the method of choice of the immunomodulatory therapy in the patients with diabetic foot syndrome.

Keywords: diabetic foot syndrome, cytokines, immunotherapy, Syperlymph
p. 65-71 of the original issue
References
  1. Балаболкин, М. И. Диабетология / М. И. Балаболкин. – М.: Медицина, 2000. –627 с.
  2. Бурлева, Е. П. Диабетическая стопа: организационные и клинические подходы / Е. П. Бурлева // Хирургия – 2003. – № 8. – С. 52-55.
  3. Комплексная диагностика и лечение диабетических остеоартропатий / В. К. Гостищев [и др.] // 1 Белорусский международный конгресс хирургов. – Витебск, 1996. – С. 379-380.
  4. Мыскина, Н. А. Процесс репарации трофических язв у больных сахарным диабетом / Н. А. Мыскина, А. Ю. Токмакова, М. Б. Анциферов // Пробл. Эндокринологии – 2004. –Т. 50, № 2. – С.34-38.
  5. Состояние иммунитета у больных сахарным диабетом с гнойно-некротическим поражением нижних конечностей // А. Б. Земляной [и др.] // Хирургия – 2002. – № 1. – С. 34-35.
  6. Котов, С. В. Диабетическая нейропатия // С. В. Котов, А. П. Калинин, И. Г. Рудакова. – М.: Медицина, 2000. – 232 с.
  7. The AGE/RAGE/NF-(kappa) pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT) / K. M. Haslbeck // Exp. Clin. Endocrinol. Diabetes – 2005. – Vol. 113 – P. 288-291.
  8. Siemionow, M. Diabetic neuropathy: pathogenesis and treatment / M. Siemionow, Y. Demir // J. Reconstr. Microsurg. – 2004. – Vol. 20. – P. 241-252.
  9. Sima, A. A. Pathological mechanisms involved in diabetic neuropathy: can we slow the process? / A. A. Sima // Curr. Opin. Investig. Drugs. – 2006. –Vol. 7 – P.324-337.
  10. Wang, Y. Proteinase-activated receptor-1 and proteinase-activated receptor-2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain / Y. Wang, W. Luo, G. Reiser // Biochem. J. – 2007 – Vol. 401. – P. 65-78.
Contacts | ©Vitebsk State Medical University, 2007